Effects of antihyperlipidemic drugs and diet plus exercise therapy in the treatment of patients with moderate hypercholesterolemia

Clinical Therapeutics

Volumn 18, Issue 3, 1996, Pages 477-482

  Nomura, Hideyuki ^a   Kimura, Youichi ^a   Okamoto, Osamu ^a   Shiraishi, Genji ^a  

^a Shin Kokura Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PANTETHINE; PRAVASTATIN; PROBUCOL;

ADULT; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DISEASE SEVERITY; EXERCISE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; ORAL DRUG ADMINISTRATION;

EID: 0029970041     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80028-2     Document Type: Article

References (20)

1. Stamler J. Research related to risk factors. Circulation. 1979;60:1575-1587.
2. Turpeinen O. Effect of cholesterol-lowering diet on mortality from coronary heart disease and other cases. Circulation. 1979;59:1-7.
3. Myasnikov AL. Influence of some factors on development of experimental cholesterol atherosclerosis. Circulation. 1958; 17:99-113.
4. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins and the risk of coronary heart disease - the Framingham study. Ann Intern Med. 1971;74:1-12.
5. Arai M, Tsujita Y. An inhibitor of cholesterol synthesis: A novel inhibitor of HMG-CoA reductase, CS-514. Ther Res. 1984; 1:669-672.
6. Tsujita Y, Kuroda M, Shimada Y. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase: Tissue selective inhibitor of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta. 1986;877:50-60.
7. Nakayama N, Honma Y, Tamachi H. The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects. JAMA. 1987;257:3088-3093.
8. Yoshino G, Kazumi T. Effect of eptastatin (CS-514) on hypercholesterolemic patients: Comparison with probucol. Curr Ther Res. 1986;40:1017-1021.
9. Mabuchi H, Kamon N. Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia. Metabolism. 1987;36: 475-479.
10. Saku K, Sasaki J, Arakawa K. Long-term effect of CS-514 (HMG-CoA reductase inhibitor) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia. Curr Ther Res. 1987; 42:491-500.
11. Miettinen TA. Mode of action of a new hypocholesterolemic drug (DH-581) in familial hypercholesterolemia. Atherosclerosis. 1972;15:163-176.
12. Simons LA. Metabolic studies with probucol in hypercholesterolemia. Atherosclerosis. 1981;40:299-301.
13. Murphy BF. Probucol (Lorelco) in treatment of hyperlipidemia. JAMA. 1977;238: 2537-2538.
14. LeLorier J, DuBreuil-Quindoz S, Lassier-Cacan S, et al. Diet and probucol in lowering cholesterol concentrations. Arch Intern Med. 1977;137:116-121.
15. Kalams Z, Dacquists M, Kornett GS. Biphenabid (probucol): A new hypocholesterolemic agent. Curr Ther Res. 1971; 13:692-694.
16. Barnhart JW, Rytter DJ, Morello JA. An overview of the biochemical pharmacology of probucol. Lipids. 1977;12:29-33.
17. Biermann EL. Atherosclerosis: Atherosclerosis and other forms of arteriosclerosis. In: Isselbacher KJ, Martin JB, Braunwald E, et al, eds. Principles of Internal Medicine. 13th ed. New York: McGraw-Hill; 1994:1108-1116.
18. Tomikawa M, Nakayasu T, Tawara K, et al. Effect of pantethine on lipoprotein profiles and HDL subfractions in experimentally hypercholesterolemic rabbits. Atherosclerosis. 1982;41:267-277.
19. Murai A, Miyahara T, Tanaka T, et al. The effects of pantethine on lipid and lipoprotein abnormalities in survivors of cerebral infarction. Artery. 1985;12:234-243.
20. Mizuno G, Hara Y, Shimizu T, et al. Preventive effects of pantethine on reduction of HDL-cholesterol caused by probucol administration. Jpn J Atheroscler Soc. 1984;12:191-197. In Japanese.